How biotech became VC's beacon of hope
March 31, 2021
As the world battled through the pandemic, VC investment in biotech and pharma thrived in 2020. The industry saw $28.5 billion invested across 1,073 deals, a 60.5% year-over-year increase, as investors recognized the importance of vaccine development.
Our latest analyst note explores how supercharged investor interest in innovative biotech startups has driven the sector beyond its early 2020 projections, and why VC-backed biotech and pharma financings are expected to remain strong this year. Among the highlights:
Our latest analyst note explores how supercharged investor interest in innovative biotech startups has driven the sector beyond its early 2020 projections, and why VC-backed biotech and pharma financings are expected to remain strong this year. Among the highlights:
- Details on recent trends that have shaped the industry, from access to public capital to the proliferation of new financing structures such as SPACs.
- Insights into the still-hot IPO market for VC-backed biotech companies, which saw $11.5 billion raised across 73 biotech public listings in 2020.
- A look at how IPOs and M&A transactions have funneled liquidity back to investors, who in turn have redeployed resources and human capital back into the biotech and pharma space.